QDOLO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for QDOLO (QDOLO).
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
| Metabolism | Primarily metabolized by CYP2D6 and CYP3A4 to active metabolite M1 (O-desmethyltramadol) and other metabolites. |
| Excretion | Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10% |
| Half-life | Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min) |
| Protein binding | Approximately 20% bound to plasma proteins, primarily albumin |
| Volume of Distribution | Steady-state volume of distribution (Vdss) approximately 3-4 L/kg, indicating extensive tissue distribution |
| Bioavailability | Oral (immediate-release): 70-90% (first-pass metabolism reduces bioavailability); Extended-release: approximately 85% relative to immediate-release; Intravenous: 100% |
| Onset of Action | Oral (immediate-release): 30-60 minutes; Oral (extended-release): 1-2 hours; Intravenous: 5-10 minutes; Intramuscular: 10-15 minutes |
| Duration of Action | Oral (immediate-release): 4-6 hours; Oral (extended-release): 12-24 hours; Intravenous: 2-4 hours; Intramuscular: 3-4 hours. Duration is dose-dependent and prolonged in hepatic impairment |
| Molecular Weight | 144.21 |
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
| Dosage form | SOLUTION |
| Renal impairment | GFR 30-49 mL/min: Administer every 8 hours. GFR 10-29 mL/min: Administer every 12 hours. GFR <10 mL/min: Administer every 12 hours; maximum 100 mg/day. Hemodialysis: Not dialyzable; dose as for GFR <10 mL/min. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50% or increase dosing interval to 12 hours. Child-Pugh Class C: Not recommended; consider alternative therapy. |
| Pediatric use | Children ≥12 years: Same as adult. Age 7-11 years: 3-5 mg/kg/day divided into 4-6 doses; maximum 200 mg/day. Age 2-6 years: 3-5 mg/kg/day divided into 4-6 doses; maximum 150 mg/day. Do not use in children <2 years. |
| Geriatric use | Adults ≥65 years: Start at 25 mg every 6 hours as needed; maximum 300 mg/day. Titrate cautiously due to risk of falls, delirium, and QT prolongation. Avoid extended-release formulations. |
| 1st trimester | Avoid; risk of neural tube defects and congenital malformations associated with first-trimester valproate exposure. |
| 2nd trimester | Use only if clearly needed; lowest effective dose; monitor for maternal hepatotoxicity and coagulopathy. |
| 3rd trimester | Avoid near term; neonatal hemorrhage, hepatic toxicity, and withdrawal syndrome reported. |
Clinical note
Comprehensive clinical and safety monograph for QDOLO (QDOLO).
| Placental transfer | Readily crosses the placenta; fetal serum levels are 1-2 times maternal levels; detectable in fetal tissues. |
| Breastfeeding | Valproate is excreted into breast milk in low concentrations (1-10% of maternal serum levels). Limited data suggest acceptable safety at therapeutic maternal doses, but monitor infant for jaundice, hepatotoxicity, and thrombocytopenia. Weigh benefits against potential risks, especially in infants with metabolic disorders. |
■ FDA Black Box Warning
Serious and life-threatening respiratory depression; accidental ingestion; risks from concomitant use with benzodiazepines or other CNS depressants; opioid addiction, abuse, and misuse; neonatal opioid withdrawal syndrome; life-threatening respiratory depression in children; ultra-rapid metabolism of tramadol and other risk factors for life-threatening respiratory depression in children.
| Serious Effects |
Hepatic disease or significant hepatic dysfunctionPersonal or family history of severe hepatic porphyriaKnown hypersensitivity to valproate or any ingredient in QDOLOUrea cycle disordersMitochondrial disorders caused by POLG mutations (e.g., Alpers-Huttenlocher syndrome)
| Precautions | Respiratory depression; risk of medication errors; addiction, abuse, and misuse; risks with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; risks of use in patients with gastrointestinal obstruction; increased intracranial pressure; impaired mental or physical abilities; withdrawal; risks of driving and operating machinery; life-threatening respiratory depression in patients with chronic pulmonary disease; risks in patients with head injury, shock, or debilitation; risks in patients with hepatic or renal impairment; risks in elderly, cachectic, or debilitated patients; pregnancy; breastfeeding; drug dependence. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Tramadol, the active ingredient in QDOLO, is classified as FDA Pregnancy Category C. First trimester: Data are limited, but animal studies have shown increased risk of skeletal variants and decreased fetal weight at doses 1.2-1.4 times the maximum human dose. Second and third trimesters: Chronic use may lead to neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth. Use near term may cause neonatal respiratory depression. Avoid in late pregnancy unless clearly needed. |
| Fetal Monitoring | Monitor for maternal respiratory depression, sedation, constipation, and opioid withdrawal. Fetal: For prolonged use, monitor for intrauterine growth restriction (IUGR) and NOWS after birth. Neonatal: Observe for respiratory depression, feeding difficulties, and withdrawal signs. Consider fetal non-stress tests if chronic use. |
| Fertility Effects | Tramadol may impair male fertility by altering sperm morphology and motility in animal studies. Human data limited; may cause hormonal imbalances (e.g., decreased testosterone). Reversible upon discontinuation. No established effects on female fertility. |
| Food/Dietary | Grapefruit juice may increase tramadol levels; avoid excessive consumption. Alcohol can potentiate CNS depression and increase risk of hepatotoxicity; avoid concurrent use. High-fat meals may delay absorption but not significantly alter overall exposure; take consistently with or without food. |
| Clinical Pearls | QDOLO is a fixed-dose combination of tramadol (37.5 mg) and acetaminophen (325 mg). Ensure acetaminophen intake from all sources does not exceed 4 g/day due to hepatotoxicity risk. Monitor for serotonin syndrome when combined with SSRIs, SNRIs, MAOIs, or triptans. Tramadol may lower seizure threshold; use with caution in patients with epilepsy or taking seizure threshold-lowering drugs. Avoid in patients with severe hepatic or renal impairment (CrCl <30 mL/min). Onset of analgesia within 1 hour, peak effect at 2-4 hours. |
| Patient Advice | Take exactly as prescribed; do not exceed 8 tablets per day. · Avoid alcohol while taking this medication. · Do not take other medications containing acetaminophen (e.g., Tylenol, cold remedies) without consulting your doctor. · Caution with driving or operating machinery until you know how the medication affects you; may cause dizziness or drowsiness. · Seek emergency care for signs of serotonin syndrome: agitation, hallucinations, rapid heart rate, fever, muscle stiffness, or loss of coordination. · Discontinue and contact doctor if seizure or signs of liver damage (yellow skin/eyes, dark urine, abdominal pain) occur. |